UBS analyst Ashwani Verma lowered the firm’s price target on Neurocrine to $125 from $137 and keeps a Buy rating on the shares. Q potential Q1 miss on Ingrezza seems to be somewhat baked in and further stock action leading up to EPS may be contingent on where expectations shake-out, the analyst tells investors in a research note. The firm’s buy side conversations indicate that Neurocrine could be a short idea going into the Q1 print, with investors viewing no upside to Ingrezza print, while next pipeline read-out at year-end presents a catalyst-lull in the interim.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Canaccord upgrades Neurocrine to Buy on 19% share pullback
- Neurocrine upgraded to Buy from Hold at Canaccord
- Neurocrine added to Analyst Focus List at JPMorgan
- Teva’s CP trial failure may add some risk for Neurocrine, says RBC Capital
- Neurocrine announces results of published study on tardive dyskinesia